Synapse - A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas

A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas Meeting Abstract

Authors:	Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; Hamlin, P. A.; Noy, A.; Matasar, M. J.; Palomba, M. L.; Younes, A.; Schaffer, W.; Grewal, R.; Rademaker, J.; Sauter, C. S.; Dahi, P. B.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Pulitzer, M.; Lubin, L.; Tang, L.; Ganesan, N.; Ni, A.; Horwitz, S. M.
Abstract Title:	A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
Meeting Title:	59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	130
Issue:	Suppl. 1
Meeting Dates:	2017 Dec 9-12
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2017-12-07
Language:	English
ACCESSION:	WOS:000432419402071
PROVIDER:	wos
DOI:	10.1182/blood.V130.Suppl_1.821.821
Notes:	Meeting Abstract: 821 -- Source: Wos